Strategic Partnering Opportunities

Concert Pharmaceuticals is applying its platform technology in deuterium chemistry to develop novel and differentiated small molecule patentable drugs. Concert has a broad pipeline of proprietary drug candidates in the areas of HIV, pain/spasticity, GI motility, infectious disease (MRSA, HCV, other) epilepsy, oncology, diabetic neuropathy, among others. Concert’s business strategy is to utilize collaborative pharmaceutical partnerships to drive these new chemical entities through development and commercialization to address unmet medical needs.

For further information please contact:
Greg Miller
Head of Business and Corporate Development
781.674.5227
BD@concertpharma.com

Current Partners
GlaxoSmithKline - 2009

Corporate Materials

• Fact Sheet: Deuterated Chemical Entity (DCE) Platform
• Publication: Innovations in Pharmaceutical Technology, "The Development of Deuterium Containing Drugs."
• Publication: Drug Discovery & Development: Chemistry for Drug Development: Deuterium Modification
  

Upcoming Events

17th Workshop of the International Isotope Society
September 23-24, 2010
Bad Soden, Germany

BioPharm America 2010
September 15-17, 2010
Boston, MA

BioNetwork West
October 25-27, 2010
Laguna Niguel, CA

[ back to top ]